EMBO of Nanjing University of Science and Technology Reveals New Targets for Psoriasis Intervention

Psoriasis ( Psoriasis ), commonly known as psoriasis, is a chronic autoimmune skin disease induced by a variety of factors such as genetics, immunity, and infection.

Sun Yang's research group has long been engaged in research on the molecular mechanism of inflammation-related diseases and targeted drug regulation.

Therefore, researchers conducted a series of studies and found that SHP2 is highly expressed on macrophages in the skin lesions of patients with psoriasis, and the enzyme activity is up-regulated.

The researchers then by single cell transcriptome sequencing and spatial transcriptome sequencing analysis, macrophages psoriasis patients and healthy skin of the PTPN11 ( of SHP2 genes encoding) and NF- [ [kappa] B are positively correlated pathway genes, This relationship does not exist in dendritic cells

Further co-immunoprecipitation experiments found that SHP2 can bind to TLR7 , so how does SHP2 affect the function of TLR7 ? The researchers first determined that SHP2 does not affect the protein expression of TLR7 , so they consider whether it affects the localization of TLR7 ? According to the endosome localization of TLR7 , the endoplasmic reticulum, Golgi apparatus and endosome were separated, and the results showed that SHP2 can promote the localization of TLR7 on the endosome

In summary, the study clarified the detailed molecular mechanism of phosphatase SHP2 to promote the progression of psoriasis, and provided a new intervention target for the development of psoriasis treatment drugs

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade